GE Healthcare Life Sciences completes acquisition of Xcellerex

GE Healthcare has announced that it has completed the acquisition of Xcellerex, a supplier of manufacturing technologies for the biopharmaceutical industry.

The acquisition expands GE Healthcare’s offering of technologies and services for the manufacture of biopharmaceuticals such as recombinant proteins, antibodies and vaccines. The strong strategic fit between the two companies, combined with expanded capabilities in product development and marketing, will offer significant customer benefits through complementary product and service offerings.

Dr Nigel Darby, Vice President of BioTechnologies and Chief Technology Officer at GE Healthcare Life Sciences, said, “Xcellerex’s expertise and reputation in technologies for biopharmaceutical manufacturing is a great fit with our business. GE and Xcellerex share a vision that an integrated approach, where we can help customers optimise every stage of their manufacturing process - from start to finish, has the potential to increase production flexibility and to deliver higher yields of finished product while reducing time to market.

“We believe that combining the skills of the two companies will bring great benefits for our customers in the industry.”